For germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer, targeting mitochondrial functions offers a promising strategy to overcome therapy resistance, which limits the efficacy of conventional treatments, including chemotherapy and PARP inhibitors [28]. This evidence concerns the gene ERBB2 and breast carcinoma.